Home / Innere Medizin / Hämatologie und internistische Onkologie / ESMO 2018: „Neoadjuvante Melanom-Studie war mein persönliches Highlight“
Univ.-Prof. Dr. Christoph Höller

ESMO 2018: „Neoadjuvante Melanom-Studie war mein persönliches Highlight“

Univ.-Prof. Dr. Christoph Höller, Universitätsklinik für Dermatologie, Wien, spricht über d a s Highlight beim Melanom, die OpACIN-neo-Studie, und diskutiert Langzeit-Studien-Updates sowie intraläsionale Therapieansätze mit TLR-9-Agonisten.


LBA44 – Overall survival at 4 years of follow-up in a phase 3 trial of nivolumab plus ipilimumab combination therapy in advanced melanoma (CheckMate 067)
F. Hodi

LBA47 – Initial results from a phase 3b/4 study evaluating two dosing regimens of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 511)
C. Lebbé

1247PD – Phase II multicenter, single arm, open label study of nivolumab in combination with ipilimumab in untreated patients with metastatic uveal melanoma (GEM1402.NCT02626962)
J.M. Piulats Rodriguez

LBA43 – Updated relapse-free survival (RFS) and biomarker analysis in the COMBI-AD trial of adjuvant dabrafenib + trametinib (D + T) in patients (pts) with resected BRAF V600–mutant stage III melanoma
G. Long

Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma; Nature Medicine 2018
C.U. Blank

LBA42 – OpACIN-neo – A Multicenter Phase 2 Study to identify the Optimal neoAdjuvant Combination scheme of Ipilimumab (IPI) and Nivolumab (NIVO).
C.U. Blank

LBA45 – Phase 1b/2, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to antiPD-1 therapy
G. Long

1245PD – Intratumoral (IT) Injection of the TLR9 agonist Tilsotolimod (IMO2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study
A. Diab

Quelle: ESMO 2018